Introduction
============

In addition to regulation of feeding, the melanin-concentrating hormone (MCH) system is an important regulator of a number of behaviors related to reward processing, addiction and other neuropsychiatric conditions such as schizophrenia and depression ([@ref-16]; [@ref-35]; [@ref-47]; [@ref-8]; [@ref-32]; [@ref-44]; [@ref-33]; [@ref-10]; [@ref-9]). The dopamine system also plays a key role in many addiction- and motivation-related behaviors and neuropsychiatric conditions ([@ref-14]; [@ref-12]; [@ref-35]; [@ref-47]; [@ref-13]; [@ref-54]). Interestingly, dopamine receptors and MCH can interact positively in the regulation of some behaviors including in animal models of cocaine addiction and schizophrenia ([@ref-8]; [@ref-10]), while antagonistic interactions are also observed ([@ref-16], see also [@ref-51]).

A recent study ([@ref-10]) examined pre-pulse inhibition (PPI), where a startle response to an intense stimulus can be suppressed when a weak stimulus (the pre-pulse) immediately precedes the intense stimulus. The PPI is used as a measure of sensorimotor gating, and significant deficits in PPI are observed in patients with schizophrenia and some other neurological disorders, which may contribute to sensory overload and related symptoms ([@ref-5]). [@ref-10] found, in mice, that MCH had no effect alone on PPI but that MCH did enhance the ability of lower doses of the DA1/DA2 dopamine receptor agonist apomorphine to suppress PPI. One implication of this finding is that simultaneous modulation of MCH and dopamine receptors might represent a novel therapy for treatment of schizophrenia, which would allow use of lower doses of dopamine modulators and thus reduce unwanted side effects. However, to fully understand the mechanism of such an interaction, it would be useful to know which brain region these dopamine and MCH agents might interact within, which could suggest additional methods through which neurons targeted by dopamine and MCH could be modulated. Dopamine and MCH receptors are present in many brain regions ([@ref-31]; [@ref-41]), and thus the region within which apomorphine and MCH might interact to suppress PPI remains unclear.

We previously used *in vitro* electrophysiology and biochemistry to show that MCH can interact cooperatively with dopamine receptor agonists to increase activity of nucleus accumbens (NAcb) shell (NAshell) medium spiny neurons ([@ref-8]). The NAshell is an important regulator of feeding, response to novelty, and some addiction- and reward-related behaviors including suppression of several forms of reward-related responding ([@ref-12]; [@ref-16]; [@ref-8]; [@ref-4]; [@ref-32]; [@ref-17]; [@ref-29]). In addition, the NAshell has been noted as a brain region which regulates PPI ([@ref-27]; [@ref-1]), including where dopaminergic drugs can disrupt PPI ([@ref-11]; [@ref-30]; but see [@ref-49]), as well as other behavioral models considered to reflect symptoms of schizophrenia such as behavioral inflexibility ([@ref-15]) and disturbances of latent inhibition ([@ref-34]; [@ref-53]).

Here, we have investigated whether MCH interacts with apomorphine to increase in action potential (AP) firing in the NAshell *in vitro*, and examined which dopamine receptors might be required for this increase in activity. A cooperative interaction between MCH and apomorphine *in vitro* could suggest that the NAshell is a brain region where MCH and apomorphine interact to suppress PPI.

Materials and Methods
=====================

Brain slice preparation and electrophysiology methods
-----------------------------------------------------

Male Sprague-Dawley rats (p21-35) were deeply anesthetized with pentobarbital (100 mg/kg, i.p.) in accordance with Institutional Animal Care and Use and National Institutes of Health Guidelines and under the guidance and approval of the IACUC Committee of the Ernest Gallo Clinic and Research Center. Transcardial perfusion was performed with ∼ 15 ml of ice-cold sucrose-aCSF (in mM: 75 sucrose, 87 NaCl, 2.5 KCl, 1.25 NaH~2~PO~4~, 7 MgCl~2~, 0.5 CaCl~2~, 25 NaHCO~3~, 1 ascorbic acid) saturated with 95% O~2~ and 5% CO~2~. The brain was rapidly removed and coronal slices (300 µm) were cut in this same sucrose-aCSF. Slices were transferred to the recovery chamber containing aCSF (in mM: 126 NaCl, 2.5 KCl, 1.2 NaH~2~PO~4~, 1.2 MgCl~2~, 2.4 CaCl~2~, 18 NaHCO~3~, 11 glucose, with pH 7.2--7.4 and mOsm 304-306) at 31 °C and saturated with 95% O~2~ and 5% CO~2~. 1 mM ascorbic acid was added to the aCSF in the recovery chamber just before adding the slices. Slices were incubated for 30 min-5 h prior to recordings.

Whole-cell current-clamp recordings were made from NAshell medium spiny neurons, identified as previously described ([@ref-22]). Patch-clamping was performed as described ([@ref-21]; [@ref-24]) using 3--5 MΩ glass electrodes filled with a potassium methanesulfonate-based internal solution (130 mM KOH, 105 mM methanesulfonic acid, 17 mM hydrochloric acid, 20 mM HEPES, 0.2 mM EGTA, 2.8 mM NaCl, 2.5 mg/ml MgATP, 0.25 mg/ml NaGTP, pH 7.2--7.4, 275--285 mOsm). Patch-clamp data were collected at 15 kHz and filtered at 2 kHz using Clampex 9.2 or 10 and a Multiclamp 700A patch amplifier (Axon Instruments, Union City, CA). During electrophysiology experiments, slices were submerged and continuously perfused (using a peristaltic pump, ∼2.5 ml/min) with carbogen-bubbled aCSF warmed to 31--32 °C, and supplemented with DNQX (10 µM, to block AMPA receptors) and picrotoxin (50 µM, to block GABA-A receptors). Here, we decided to use a concentration of 2 µM α-flupenthixol, a D1/D2 receptor antagonist. Previous reports have reported divergent concentrations of α-flupenthixol in slice experiments (10 µM in [@ref-6], 0.1 µM in [@ref-2]). Also, behavioral experiments injecting α-flupenthixol into the NAcb tend to use higher concentrations (≥5 µg, [@ref-14]; [@ref-42]) relative to that used for SCH23390 or raclopride (1--2 µg, see [@ref-55]). Thus, we chose 2 µM, which is somewhat higher than the 1 µM we use for SCH23390 and raclopride *in vitro*. In addition, α-flupenthixol had no effect of firing on its own ([Fig. 2C](#fig-2){ref-type="fig"}, −0.3 ± 2.3% change in firing versus basal, *P* = 0.116 paired *t*-test), in agreement with our previous studies that blockers more selective for D1 or D2 receptors have no effect on firing on their own in the NAshell ([@ref-22]).

![Increased NAshell firing with apomorphine and MCH.\
(A, B) (A) Example traces and (B) grouped data across time showing that 1 µM MCH (MCH) and 3 µM apomorphine (Apo3) interact to enhance firing in NAshell neurons *in vitro*, while 3 µM apomorphine had no effect alone. (C) 10 µM apomorphine (Apo10) was sufficient to enhance NAshell firing. (D) 1 µM MCH in combination with 1 µM apomorphine did not increase firing. (E) 1 µM MCH in combination with 10 µM apomorphine significantly increased firing. (F) 3 µM apomorphine in combination with 1 µM MCH significantly enhanced firing under conditions where AMPA and GABA~A~ receptors were not blocked. (G) 3 µM apomorphine + 1 µM MCH did not increase firing when the PKA inhibitor peptide PKI (20 µM) was included in the intracellular pipette.](peerj-01-61-g001){#fig-1}

![Dopamine receptor inhibitors prevent the apomorphine/MCH enhancement of firing.\
Enhancement of NAshell firing by MCH (1 µM) + apomorphine (3 µM) was prevented by pre-exposure to (A) the DA1 receptor blocker SCH23390 (SCH, 1 µM), (B) the DA2 receptor blocker raclopride (Racl, 1 µM), (C) the D1/D2 blocker α-flupenthixol (flupen, 2 µM), or (D) the MCH receptor blocker TPI (2 µM).](peerj-01-61-g002){#fig-2}

AP generation, analyses and statistics
--------------------------------------

The resting membrane potential was determined just after breaking into a neuron, and each neuron was then brought to a resting potential of ∼−85 mV by passage of DC current via the patch amplifier before further firing experiments. To generate APs, neurons in current clamp were depolarized with a series of 7 or 8 500-ms current pulses, with 20 pA between each current pulse, and where the initial current pulse for each neuron was just sub-threshold for firing. This series of current pulses was applied every 30 s throughout the experiment, and was alternated with hyperpolarizing steps (−50 and −100 pA) to examine input resistance.

To analyze changes in firing for each cell, a depolarizing step was chosen that gave ∼6--7 APs in the basal condition. We then determined the number of APs at this current step at all time points during the experiment for that cell. The baseline firing rate was determined from the average of firing in the 4 min before addition of apomorphine ± MCH, and was normalized to 100% for each cell. The percent change in firing versus baseline was then determined by taking the average of firing during the 6th--8th min of apomorphine ± MCH exposure. Statistics across groups were determined using these averaged values for the peak change in firing. Thus, a one-way ANOVA was calculated comparing 3 µM apomorphine + MCH with and without dopamine or MCH receptor blockers, and also comparing with 3 µM apomorphine alone; Tukey was used as a post-hoc. *P* \< 0.05 was taken to indicate significant differences. Data are shown as mean + /− SEM.

Results
=======

To examine whether apomorphine and MCH interacted *in vitro* to alter AP firing in NAshell neurons, we performed *in vitro* whole-cell patch-clamp electrophysiology experiments in brain slices containing NAshell medium spiny neurons. A series of 500 ms depolarizing steps of varying current intensity were applied every 30 s (see Methods) to generate AP firing. As shown in [Figs. 1A](#fig-1){ref-type="fig"} and [1B](#fig-1){ref-type="fig"}, 3 µM apomorphine did not enhance NAshell firing on its own (*n* = 7, 0.2 ± 3.8% change in firing versus basal), although 10 µM apomorphine was sufficient to enhance firing ([Fig. 1C](#fig-1){ref-type="fig"}, *n* = 7, 24.2 ± 8.4% change in firing versus basal, paired *t*-test *P* = 0.021 baseline versus 10 µM apomorphine). In contrast, 3 µM apomorphine significantly enhanced firing when combined with 1 µM MCH ([Figs. 1A](#fig-1){ref-type="fig"} and [1B](#fig-1){ref-type="fig"}, *n* = 7, 24.4 ± 7.8% change in firing versus basal, *P* \< 0.01 versus 3 µM apomorphine alone). We also found that 1 µM MCH in combination with 10 µM apomorphine significantly increased firing ([Fig. 1E](#fig-1){ref-type="fig"}, *n* = 5, 29.5 ±6.3% change in firing versus basal, *P* = 0.010 paired *t*-test). 1 µM MCH in combination with 1 µM apomorphine did not change firing ([Fig. 1D](#fig-1){ref-type="fig"}, *n* = 6, 0.7 ± 2.8% change in firing versus basal, *P* = 0.798 paired *t*-test), suggesting that a minimal amount of dopamine receptor activation was required to interact with MCH to increase NAshell firing. Previous studies ([@ref-8]; [@ref-44]) have shown that MCH either does not increase firing ([@ref-8]) or reduces firing ([@ref-44]) in the NAshell when applied alone; in either case it does not enhance NAshell firing when applied alone. Thus, our results suggest that MCH can interact with a sub-threshold dose of apomorphine (3 µM) to increase NAshell firing *in vitro*.

Since our experiments were performed in the presence of DNQX to inhibit spontaneous AMPA receptor activation and picrotoxin to inhibit spontaneous GABA~A~ receptor activation ([@ref-22]; [@ref-23]), we next examined whether 3 µM apomorphine in combination with 1 µM MCH increased firing in the absence of these blockers, which might reflect more physiological conditions. As shown in [Fig. 1F](#fig-1){ref-type="fig"}, apomorphine + MCH did significantly enhance firing under conditions where AMPA and GABA~A~ receptors were not blocked (*n* = 5, 30.3 ± 9.6% change in firing versus basal, *P* = 0.030 paired *t*-test), suggesting that the ability of apomorphine + MCH to enhance firing persisted even when AMPA and GABA~A~ receptors could be modulated by possible dopaminergic effects on spontaneous release ([@ref-36]; but see [@ref-38]) or spontaneous activity of GABA interneurons ([@ref-7]).

A number of studies suggest that PKA is an central regulator of NAcb dopaminergic signaling ([@ref-48]) including dopamine receptor enhancement of NAshell firing ([@ref-22]). In agreement, the increase in firing with 3 µM apomorphine + MCH was prevented by including the PKA inhibitor peptide PKI (20 µM, [@ref-23]) in the intracellular pipette solution ([Fig. 1G](#fig-1){ref-type="fig"}; *n* = 5, 2.1 ± 5.1% change in firing versus basal, *P* = 0.030 vs no PKI in [Fig. 1B](#fig-1){ref-type="fig"}).

We next determined whether the apomorphine + MCH increase in firing required dopamine type 1 (DA1) and/or dopamine type 2 (DA2) receptors. Application of 3 µM apomorphine + MCH did not increase firing after 10 min pre-exposure to a blocker for DA1 receptors ([Fig. 2A](#fig-2){ref-type="fig"}, SCH23390 1 µM, *n* = 5, −3.9 ± −2.2% change in firing versus basal), a blocker for DA2 receptors ([Fig. 2B](#fig-2){ref-type="fig"}, raclopride 1 µM, *n* = 6, −0.1 ± 8.2% change in firing versus basal) or a blocker that targets both DA1 and DA2 receptors ([Fig. 2C](#fig-2){ref-type="fig"}, α-flupenthixol 2 µM, *n* = 4, −4.2 ± 3.4% change in firing versus basal). The increase in NAshell with 3 µM apomorphine + MCH was also prevented by pre-exposure to the MCH receptor inhibitor TPI (2 µM, [@ref-8]) ([Fig. 2D](#fig-2){ref-type="fig"}, *n* = 6, 3.0 ± 2.4% change in firing versus basal), confirming the importance of MCH receptors in the action of apomorphine + MCH. A one-way ANOVA comparing the groups shown in [Fig. 3](#fig-3){ref-type="fig"} found a significant effect across groups (*F*(5, 29) = 4.140, *P* = 0.006), and post-hoc analyses showed that the 3 µM apomorphine + MCH enhancement in firing was significantly prevented by pre-exposure to any of the four receptor blockers tested here (*P* \< 0.05). Together, these results suggest that MCH in combination with 3 µM apomorphine was able to enhance firing in NAshell neurons, and that this increase in firing required activity at both DA1 and DA2 receptors as well as MCH receptors and PKA.

![ANOVA for dopamine receptor mediation of apomorphine/MCH enhancement of firing.\
Significant effect (\**P* \< 0.05) of MCH +apomorphine (3 µM) versus 3 µM apomorphine alone or versus MCH + 3 µM apomorphine after pre-exposure to antagonists for DA1 (SCH), DA2 (Racl), DA1/DA2 (flupen) or MCH (TPI) receptors.](peerj-01-61-g003){#fig-3}

To further explore the mechanism underlying the apomorphine/MCH increase in firing, we analyzed the input resistance and several aspects of the action potential waveform from all agonist conditions that enhanced action potential firing ([Table 1](#table-1){ref-type="table"}). In agreement with our previous work ([@ref-22]), increases in firing with apomorphine/MCH were not accompanied by any changes in these parameters, suggesting that the apomorphine/MCH increase in firing did not reflect alterations in inward rectifying channels or sodium or fast potassium channels active during an action potential ([@ref-22]; [@ref-24]).

10.7717/peerj.61/table-1

###### Enhancement of firing with apomorphine + /− MCH was not accompanied by changes in input resistance (Rinput) or several action potential waveform parameters.

(*P* value for paired *t*-test comparisons between values at baseline and values after addition of apomorphine + /− MCH). Analyses were only performed under conditions where firing was enhanced. "Apo3 + MCH without blockers" indicates experiments where Apo3 + MCH was added in the absence of picrotoxin and DNQX. "AP" indicates action potential, and waveform parameters were determined as previously described ([@ref-22]; [@ref-24]). Although there is some variability among groups in terms of basal input resistance, a one-way ANOVA found no differences in basal input resistance across the four groups tested (*F*(3, 20) = 1.102, *P* = 0.372).

![](peerj-01-61-g004)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Measure                     Basal          Apo3 + MCH      Basal          Apo10           Basal          Apo10 + MCH     Basal          Apo3 + MCH\
                                                                                                                                          without blockers
  --------------------------- -------------- --------------- -------------- --------------- -------------- --------------- -------------- ------------------
  Rinput (MΩ)                 174.6 ± 21.4   184.6 ± 21.0\   158.7 ± 28.0   164.1 ± 31.3\   127.8 ± 16.8   143.8 ± 18.4\   126.8 ± 14.8   129.9 ± 14.7\
                                             *P* = 0.083                    *P* = 0.345                    *P* = 0.149                    *P* = 0.554

  AP amplitude (mV)           80.9 ± 2.5     78.8 ± 3.6\     79.1 ± 1.6     78.7 ± 1.5\     82.4 ± 3.1     80.8 ± 4.7\     78.8 ± 2.5     77.4 ± 3.6\
                                             *P* = 0.168                    *P* = 0.583                    *P* = 0.430                    *P* = 0.083

  AP threshold (mV)           −45.5 ± 1.7    −46.2 ± 2.3\    −47.3 ± 2.3    −48.1 ± 2.5\    −46.2 ± 1.2    −47.7 ± 1.1\    −44.6 ± 2.6    −45.5 ± 2.4\
                                             *P* = 0.343                    *P* = 0.097                    *P* = 0.077                    *P* = 0.182

  AP half-width (ms)          1.85 ± 0.16    1.79 ± 0.09\    1.77 ± 0.09    1.83 ± 0.08\    1.77 ± 0.06    1.82 ± 0.09\    1.83 ± 0.11    1.82 ± 0.13\
                                             *P* = 0.523                    *P* = 0.319                    *P* = 0.278                    *P* = 0.983

  Peak of the fast AHP (mV)   −59.5 ± 2.3    −59.8 ± 3.0\    −63.1 ± 1.5    −63.3 ± 1.6\    −60.3 ± 1.8    −61.4 ± 1.9\    −58.3 ± 3.1    −58.5 ± 3.0\
                                             *P* = 0.700                    *P* = 0.603                    *P* = 0.240                    *P* = 0.449
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

Using *in vitro* whole-cell patch-clamp electrophysiology, we found that MCH and apomorphine in combination enhanced firing of NAshell neurons; an increase in firing was not observed with this concentration of apomorphine on its own, and MCH alone was previously shown not to increase NAshell firing ([@ref-8]; [@ref-44]). We also found that the increase in NAshell firing with apomorphine + MCH was inhibited by antagonists of either DA1, DA2, or MCH receptors or by an agent that blocks both DA1 and DA2 receptors. These results concur with our previous findings that DA1 and DA2 receptors interact to enhance NAshell activity ([@ref-22]; [@ref-23]; [@ref-8]) (see also [@ref-45] in the NAcb core and [@ref-26]), and suggest that apomorphine enhancement of firing required both DA1 and DA2 receptors in addition to an interaction with MCH receptors. The apomorphine + MCH increase in firing was prevented by a PKA inhibitor, consistent with previous work showing that PKA is an important mediator of NAcb dopaminergic signaling involving DA1 receptors ([@ref-48]), including dopamine receptor enhancement of NAshell firing ([@ref-22]). Our results also suggest that the NAshell may represent the brain region where lower doses of apomorphine can interact with MCH *in vivo* to suppress PPI ([@ref-10]).

We previously showed that MCH in combination with both DA1 and DA2 receptor agonists significantly enhanced NAshell firing *in vitro* ([@ref-8]), but we did not determine whether DA1 or DA2 might itself be sufficient to interact with MCH to enhance firing. Thus, the present results with DA receptor antagonists provide new information that apomorphine activation of both DA1 and DA2 receptors was required for apomorphine to interact with MCH to enhance firing. This agrees with our previous work that dopamine enhancement of firing can be prevented by either DA1 or DA2 receptor antagonists ([@ref-22]). We should note that the DA1 receptor blocker SCH23390 has been shown to directly inhibit GIRK channels ([@ref-28]). However, when acting through this mechanism, SCH23390 directly depolarizes cells and enhances action potential firing; we observed no effect of SCH23390 alone on firing in a previous study ([@ref-22]) or here with a shorter baseline period before adding SCH23390, suggesting that SCH23390 did not directly alter GIRK function under the conditions studied here.

Our results suggesting a DA1/DA2 interaction to increase firing also agree with a larger behavioral literature that has shown that a number of behaviors are mediated through a DA1/DA2 interaction in the NAcb (e.g. [@ref-37]; [@ref-3]; [@ref-46]; [@ref-20]), and for cocaine-primed reinstatement ([@ref-43]) and intra-NAshell self-administration of dopamine receptor activators ([@ref-25]), DA1 and DA2 receptors interact cooperatively to support behavior. In contrast, some behaviors are regulated differentially by DA1 and DA2 receptors in the NAcb ([@ref-18]; [@ref-39]; [@ref-19]); at a cellular level, DA1 and DA2 receptors can have divergent effects, e.g., on glutamate receptor function ([@ref-16]; [@ref-18]; [@ref-44]; [@ref-52]). Here, we found that apomorphine + MCH increased firing when AMPA and GABA~A~ receptors were not blocked pharmacologically, suggesting that the increase in firing still occurred in the presence of any possible dopaminergic effects on glutamate or GABA~A~ receptors due to spontaneous release ([@ref-36]; but see [@ref-38]) or spontaneous activity of GABAergic interneurons ([@ref-7]). Although the mechanism through which DA1 and DA2 receptors in the NAcb might interact positively under some conditions remain unclear, studies have described a mechanism requiring DA1-DA2 heterodimers ([@ref-20]) or G protein beta-gamma subunits ([@ref-22]; [@ref-26]) and PKA (here; [@ref-22]; [@ref-26]).

We should also note that studies of MCH alone on NAshell activity have yielded somewhat mixed results. We found that MCH alone did alter neuronal firing or the levels of phospho-DARPP but that MCH in combination with dopamine receptor agonists enhanced both measures ([@ref-8]). In contrast, Sears and colleagues ([@ref-44]) found that MCH alone can inhibit firing and phospho-GluR1 in the NAshell. Although the reason for these mixed results is not completely apparent, it is possible that MCH would be able to modulate firing when combined with activation of dopamine receptors but have different effects on firing when applied alone. Such divergent effects of receptor agonists alone versus in combination with other types of receptor agonists has previously been shown, for example as shown with adenosine/cannabinoid receptor interactions ([@ref-50]).

Conclusion
==========

We found that MCH interacted with subthreshold levels of the dopamine receptor agonist apomorphine to enhance firing of NAshell neurons *in vitro*. Apomorphine + MCH enhancement of NAshell firing required both DA1 and DA2 receptors as well as MCH receptors. Our *in vitro* results parallel what is observed *in vivo* where MCH enhances the ability of lower doses of apomorphine to suppress PPI, an animal model for some aspects of schizophrenia in humans. Thus, the NAshell may represent the brain region where MCH and apomorphine interact to regulate the expression of PPI and thus could regulate some symptoms of human schizophrenia. Apomorphine within the NAshell can also reduce withdrawal-related anxiety ([@ref-40]), suggesting that this mechanism might be relevant to other psychiatric diseases such as depression which are modulated through MCH ([@ref-16]; [@ref-35]; [@ref-47]; [@ref-8]; [@ref-32]; [@ref-44]; [@ref-33]; [@ref-10]; [@ref-9]).
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